Navigation Links
UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
Date:10/11/2007

sed sodium excretion versus baseline (28%, 138%, 55% and 158% average change, respectively) and increased plasma cGMP versus baseline (4%, 202%, 378% and 691% average change, respectively).

With respect to safety assessments, CD-NP (placebo, 10, 17.5 and 25 ng/kg/min) had no effect on mean arterial pressure versus baseline (-5%, 6%, -6%, -8% average change, respectively), had no effect on serum potassium levels versus baseline (0%, -2%, 3%, 3% average change, respectively), and had no effect on renal function as measured by GFR versus baseline (1%, 8%, 3%, 4% average change, respectively).

The four-hour infusion of CD-NP was well tolerated in all subjects at all dose levels tested. At the highest dose (25 ng/kg/min) of CD-NP, after completing the four-hour infusion, in response to an orthostatic challenge, some subjects exhibited transient symptoms consistent with volume depletion and/or vasodilatation including dizziness, asymptomatic tachycardia and orthostatic hypotension. These events are indicative of a practical limit of pharmacologic activity in normal healthy subjects, and Nile intends to investigate higher doses in upcoming Phase 1b studies of CD-NP infusions in heart failure patients.

"In this trial in healthy subjects, we demonstrated that CD-NP can be safely administered and elicits pharmacological and clinical effects which are consistent with the proposed mechanism of action. We are planning additional phase 1 trials in heart failure patients with the goals of determining the therapeutic dose range for diuresis, natriuresis, and cardiac filling pressure reducing effects, while maintaining systemic blood pressure and preserving renal function," commented Peter Strumph, Chief Executive Officer of Nile.

About CD-NP

CD-NP is a rationally-designed synthetic peptide designed to incorporate the optimal components of naturally occurring natriuretic peptides, creating a novel compound with unique actions in vivo. CD-NP is a selecti
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014 Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today that on December 24, 2014 it ... The Company raised approximately $2.3 million in ... use the net proceeds from the offering to ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 /PRNewswire/ ... biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for ... need and commercial potential, today announced that it ... shares of its common stock and Series C ... stock.  Funds under the management of QVT Financial ...
(Date:12/24/2014)... 23, 2014  Advanced Medical Isotope Corporation ("AMIC") ... in the development of brachytherapy devices and medical ... that it has filed a de novo ... ("FDA") for marketing clearance for its patented Y-90 ... U.S. Food, Drug and Cosmetic Act (the "Act").  ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... March 1, 2012 Today, the Pharmacy Technician ... Survey to collect feedback from the pharmacy profession ... Recommendations include the creation of specialty pharmacy technician ... as requiring a minimum period of practical experience, ...
... Corporation (NYSE: BSX ) announces the ... Coronary Stent System in Japan.  The product was ... and Welfare.  The PROMUS Element Stent System incorporates ... stent design and an advanced catheter delivery system ...
Cached Medicine Technology:PTCB Calls For Profession-wide Feedback on Proposed Changes to Certification Program 2Boston Scientific Announces Launch of PROMUS Element™ Platinum Chromium Stent System in Japan 2Boston Scientific Announces Launch of PROMUS Element™ Platinum Chromium Stent System in Japan 3Boston Scientific Announces Launch of PROMUS Element™ Platinum Chromium Stent System in Japan 4
(Date:12/24/2014)... National (PRWEB) December 25, 2014 Over ... back to their local communities. That is 700 smiling ... a single gift. Additionally over $6000 in monetary donations ... help offset some of the expenses they incur through ... years drive were A Child's Haven , Shrine's ...
(Date:12/24/2014)... Connie Casad, MD, a well-known and respected gynecologist, ... years of practice experience in Dallas, Texas, has announced ... dietary detoxification. The second study is scheduled to begin ... test patients who just completed a 21-day detoxification regimen. ... conducting the study, Dr. Casad said, "About 10 years ...
(Date:12/24/2014)... New York (PRWEB) December 24, 2014 ... mount in a mass tort litigation currently underway in ... reports. As of December 24, 2014, court documents ... proceeding on behalf of individuals who developed gynecomastia (male ... use. Data from the Court indicates that this represents ...
(Date:12/24/2014)... 24, 2014 Dr. Vu Ho, a ... of his practice and med-spa with the addition of ... list of cosmetic treatments and services. , “Silk Peel ... skin,” says Dr. Ho. “As a result it can ... wrinkles, sun spots, discolorations or blemishes.” , Similar to ...
(Date:12/24/2014)... UWDress.com, the famous women’s dress supplier, has presented its new ... wedding gown promotion. , For those who prefer ... way, the collection should be a great choice. The dresses ... they are available with custom service. , Now, all the ... to 75% off; most of them come in hot designs. ...
Breaking Medicine News(10 mins):Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2
... for the Bush administration and therefore many issues are closing ... by the American Civil Liberties Union; they have asked for ... ‘Abstinence Only Sex Education’ programme. ,The ACLU put forward ... Dr. John Santelli, a pediatrician at the Mailman School of ...
... the super bug hounding them relentlessly. While patients battling ... are quite ‘sick’ with the alien invasion. Of particular ... Clostridium difficile, which networks with gusto among the NHS ... lives annually is also known for its caprice and ...
... a drug that can switch on a gene to burn body ... now pop a pill and burn away all the unwanted fat. ... Biological Studies, California in the US points in that direction. ... even when they did not exercise, and were resistant to weight ...
... patient care. In a recent report the use of RFID (Radio ... who succumb to sudden infant death syndrome each year. ... has come up with a new solution for sudden infant death ... his friends developed a device that can warn a parent when ...
... but also power according to a //recent report. ... retorts, "And you always decide which movie we see." Arguments ... problem only when they are not about specific grievances, but ... Tanja Boeckling, a relationship counselor from Koblenz. Influence must be ...
... Researchers in Melbourne have found a breakthrough method of blood ... measuring the proteins //in blood much before the symptoms arrive. ... Institute, Mental Health Research Institute and Melbourne University specialists. ... which has a broader application as it can screen many ...
Cached Medicine News:Health News:A New Pill to Burn Away Unwanted Fat 2Health News:RFID Use can Avoid Sudden Infant Death Syndrome 2Health News:Relationships are Built on Love and Power 2Health News:New Blood Test to Diagnose Parkinson Disease 2
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... Powerwave is the first microplate spectrophotometer designed ... 7 days per week. With rugged hardware, ... Powerwave breaks the barrier of traditional spectrophotometry ... One instrument can easily read up to ...
The PerkinElmer LS 45 Luminescence spectrometer offers versatility, reliability and ease-of-use for routine analyses in an affordable package....
Spectra 2000 Digital Spectrophotometer is designed for quantitative and qualitative analysis in visible range from 320 nm to 1020 nm....
Medicine Products: